ProCE Banner Activity

Phase III CASSINI: Rivaroxaban vs Placebo as VTE Prophylaxis in Ambulatory Patients With Cancer

Slideset Download
Conference Coverage
In ambulatory patients with cancer, rivaroxaban significantly reduced VTE with a low incidence of major bleeding, and with the use of the Khorana score cutoff of 2 or higher identifying patients at high risk of thrombotic events.

Released: December 11, 2018

Expiration: December 10, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology